Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

• DOI: 10.1136/jitc-2023-006755
• Publication Date: 2023-05-22T14:37:59Z
• Authors: Cathrine Lund Lor...; Julie Westerlin K...; Eva Ehrnrooth; Mads Hald Andersen; Inge Marie Svane
• Keywords: Peptide vaccine

We have previously published initial efficacy of the indoleamine 2,3-dioxygenase (IDO)/anti-programmed death ligand 1 (PD-L1) vaccine in combination with nivolumab 30 anti-PD-1 therapy naïve patients metastatic melanoma (cohort A). now report long-term follow-up cohort A. Further, we results from B, where peptide was added to for progressive disease during treatment.